Hemagglutination Inhibition Tests

• 

  Subject Areas on Research

  • A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface. 
  • A seroepidemiological study of pandemic A/H1N1(2009) influenza in a rural population of Mali. 
  • Accelerated rejection of skin grafts in recipients sensitized with extracted human histocompatibility antigens. 
  • Cigarette smoking and hemagglutination inhibition response to influenza after natural disease and immunization. 
  • Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. 
  • Comparison of glycoproteins isolated by phenol-water partition of human erythrocyte membranes. 
  • Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. 
  • Development of a monoclonal antibody specific for serotype 3 rotavirus strains. 
  • Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. 
  • Hereditary alterations in the immune response: coexistence of "agammaglobulinemia", acquired hypogammaglobulinemia and selective immunoglobulin deficiency in a sibship. 
  • Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. 
  • Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. 
  • Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. 
  • Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort. 
  • Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine. 
  • Measurement of fibrinogen degradation products. 
  • Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. 
  • Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. 
  • Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. 
  • Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. 
  • Systems biology of vaccination for seasonal influenza in humans. 
  • The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. 
  • The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface. 
  • Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. 
  • West Nile virus in Mexico: evidence of widespread circulation since July 2002. 
  • [The new approach to rubella in pregnancy].